Corcept Therapeutics Inc's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Corcept Therapeutics Inc in the second quarter 2026?
Corcept Therapeutics Inc achieved a return on average equity (ROE) of 8.27 % in its second quarter 2026, this is above CORT's average return on equity of -59.13%.
Corcept Therapeutics Inc shareholder's equity over the 12 months ending in its second quarter 2026 are valued at $656 million

ROE has advanced compared to 7.31% in the first quarter 2026, due to net income growth.

Within the Major Pharmaceutical Preparations industry 56 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 1704 to 1715.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Equity Change	11.01 %	-6.63 %	-4.68 %	-1.09 %	-
Y / Y Net Income Change	21.76 %	-	-21.36 %	-58.54 %	-1.45 %
Net Income (TTM) in Millions	54	47	98	105	132
Return On Equity (TTM)	8.27 %	7.31 %	15.11 %	15.92 %	20.02 %
CORT's Total Ranking	# 1715	# 1704	# 610	# 624	# 557
Equity (TTM) in Millions	706	638	648	632	636
Seq. Equity Change	10.63 %	-1.52 %	2.52 %	-0.61 %	-6.95 %
Seq. Net Income Change	-	-	23.52 %	-44.07 %	70.6 %

Back to CORT Management Effectiveness >> CORT's 5 Years Annual ROE >> Compare CORT ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 57
Sector	# 155
Overall	# 1715

Return On Equity Statistics
High	Average	Low
131.42 %	-59.13 %	-1546.34 %
(Dec 31 2017)		(Dec 31 2014)

CORT Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	648	680	507	502	376
Y / Y Equity Change	-4.68 %	34.12 %	0.97 %	33.54 %	-28.19 %
Net Income in Millions	98	140	105	101	113
Y / Y Net Income Change	-29.74 %	32.45 %	4.15 %	-9.98 %	6.13 %
Return On Equity	15.15 %	20.56 %	20.82 %	20.18 %	29.94 %

Back to CORT Management Effectiveness >> CORT's 5 Years Annual ROE >> Compare CORT ROE to its Competitors

Annual Roe Comment

In 2025 ROE decreased compared to the previous year to 15.15 %, due to deterioration of net income.

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
CORT's' Return on Equity at Yahoo Finance
CORT's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for CORT's Competitors
Subscribers only: Roe for Corcept Therapeutics Inc's Suppliers
Subscribers only: Return On Equity for CORT's Customers

Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector	ROE
Prestige Consumer Healthcare Inc	21.77 %
Jazz Pharmaceuticals Plc	21.37 %
Neurocrine Biosciences Inc	21.13 %
Universal Health Services Inc	20.89 %
Puma Biotechnology Inc	20.85 %
Entera Bio Ltd	20.82 %
United Therapeutics Corporation	20.18 %
Ligand Pharmaceuticals Incorporated	20.06 %
Harmony Biosciences Holdings inc	20.06 %
Pediatrix Medical Group Inc	19.89 %
Theravance Biopharma inc	19.40 %
Krystal Biotech Inc	19.34 %
Ani Pharmaceuticals Inc	19.33 %
Brightspring Health Services Inc	18.93 %
Sbc Medical Group Holdings Incorporated	18.69 %
West Pharmaceutical Services Inc	18.51 %
Intuitive Surgical Inc	17.82 %
Standard Biotools Inc	17.64 %
Inspire Medical Systems inc	17.62 %
Medinotec Inc	17.47 %
Lemaitre Vascular Inc	16.93 %
Ufp Technologies Inc	16.72 %
Ensign Group Inc	16.53 %
Stryker Corp	16.36 %
Nephros Inc	16.20 %
Spero Therapeutics Inc	16.17 %
Progyny Inc	15.98 %
Collegium Pharmaceutical Inc	15.96 %
Alpha Pro Tech Ltd	15.43 %
Livanova Plc	15.41 %

Date modified: 2026-08-13T08:10:46+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.